DexCom, Inc. (DXCM) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Wait for pullback to $57.85. At $66.34 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.85 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers.
DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7 15 Day, and Stelo (OTC) as current products. Sales of CGM systems are expected to account for substantially all product revenue; reimbursement comes from... Read more
Wait for pullback to $57.85. At $66.34 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.85 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers. Chart setup: Death cross but MACD improving, RSI 66. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.13, quality 8.4/10, growth 8.1/10). Score 6.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, positive momentum, no SEC red flags, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — DexCom, Inc.
Latest news
- Why DexCom (DXCM) is a top value stock for the long term - MSN — MSN positive
- DXCM Earnings Preview: DexCom Q2 2026 on April 30 - Meyka — Meyka neutral
- Vanguard Group Inc. Has $3.26 Billion Stock Holdings in DexCom, Inc. $DXCM - MarketBeat — MarketBeat neutral
- DexCom (DXCM) Q1 Earnings: What To Expect - StockStory — StockStory neutral
- DexCom (DXCM) Q1 Earnings: What To Expect - FinancialContent — FinancialContent neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCGM systems10-K Item 1A: 'We expect that sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future.'
- HIGHSuppliersingle- or sole-source key suppliers10-K Item 1A: 'our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers'
Material Events(8-K, last 90d)
- 2026-03-02Item 5.02LOWKevin Sayer (Executive Chairman) returned from temporary leave effective March 2, 2026, resuming duties. Letter Agreement signed. Mark Foletta resumed duties as Lead Independent Director upon Sayer's return. No departure.SEC filing →
- 2026-02-26Item 5.02LOWAlbert F. ('Rick') Osterloh IV appointed as new Board director effective February 26, 2026, also appointed to Compensation Committee and Technology Committee. No family relationship or related party transactions disclosed.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $57.85. At $66.34 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $57.85 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers. Chart setup: Death cross but MACD improving, RSI 66. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 1.13, quality 8.4/10, growth 8.1/10). Target $73.48 (+10.8%), stop $52.87 (−25.5%), Setup A.R:R 2.1:1. Score 6.3/10, moderate confidence.
Take-profit target: $73.48 (+14.7% upside). Target $73.48 (+10.8%), stop $52.87 (−25.5%), Setup A.R:R 2.1:1. Stop-loss: $52.87.
Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source key suppliers; Below 200-MA, MA slope -4.8%/30d (confirmed downtrend).
DexCom, Inc. trades at a P/E of 28.7 (forward 21.9). TrendMatrix value score: 5.2/10. Verdict: Buy (Wait for Entry).
37 analysts cover DXCM with a consensus score of 4.2/5. Average price target: $82.
What does DexCom, Inc. do?DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7...
DexCom designs and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with the G7, G7 15 Day, and Stelo (OTC) as current products. Sales of CGM systems are expected to account for substantially all product revenue; reimbursement comes from Medicare, Medicaid, and commercial insurers for the G7 and G7 15 Day systems.